Audit: QRS - Butcher’s Broom for Health & Longevity

Audit conducted on 17/08/2026 09:12 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 365, 367, 375; time cells to ER 400/422; benefits to ER 160–208; risks to ER 238–286; gates to ER 308–339; markers and cadence to ER 454–464; qualitative items to ER 468–473.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER hedge is dropped in a way that changes meaning; speculative tiers carry the ER’s own speculative items.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications and cautions remain cautions; thresholds (≥160/100 mmHg, >3× upper limit of normal, 12 months) are carried unchanged.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications; no modifying factor is promoted into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The only proper name used, “Pierre Fabre” in [action_2_label], is the ER’s own bold label at ER line 367; no PMIDs, NCT numbers or product brand names are introduced.
1.6	The QRS does not introduce new attributions.	🟢	No author, society, guideline or manufacturer attribution appears beyond the ER’s own protocol label.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER; the ER’s commercial-entanglement caveat is carried into [at_a_glance].
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Precise clinical terms in Monitoring, plain terms in At-A-Glance; benefits and risks both surfaced without alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as evidence and protocol description, not instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative advice; protocol cells describe regimens used in trials and monographs.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised” or “should” constructions in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only where they are the marker or drug-class name; At-A-Glance is entirely plain.
2.8	Information is presented in a concise and very compact manner	🟢	All items are noun phrases or short clauses; no ER explanations carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”/”we”/”our”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges rather than conventional lab cut-offs, and a 12-week self-measurement protocol, address exactly this reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily dosing, evening fixed-landmark ankle measurement and repeat liver panels are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring targets (<25 U/L alanine aminotransferase, <5.4% glycated haemoglobin) are tighter than population reference ranges.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	[at_a_glance] and [risks_medium] both foreground that symptom relief occurs without disease modification, the decision-relevant point for this reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Health & Longevity” in title and header; no occurrence of “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“capsule”, “alanine aminotransferase”, “lymphoedema”, “vasoconstriction”; the one informal-looking phrase, “pins-and-needles”, is the ER’s own wording at ER line 470.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at QRS lines 446, 490, 539, 568, 583, 611, 636, 640–642, 754 and in the tier <strong> labels.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Variable-name diff against the template shows full coverage; marker_#_* expanded to marker_1–7 and qualitative_item_# to items 1–6 as designed.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	<span website="evidence_review">, <span website="audit"> and <span website="full_review"> are unchanged; structural diff against the template shows no CSS, heading or markup edits.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	[action_1_label], [action_2_label], [action_3_label] and [time_3_label] reproduce the ER bold labels at ER lines 365, 367, 375 and 400 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	[time_1_label] “Leg symptoms” and [time_2_label] “Swelling” name the two aspects inside the ER’s single Time to effect bullet (ER line 422) using the ER’s own nouns; no label is invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns no emoji; the ER’s “⚠️ Conflicted” marker on the Medium benefit is correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: 11 ER interaction bullets reduced to 10 one-line items, 8 contraindications stripped of their em-dash clauses, and the ER’s 7-row biomarker table reduced to marker/target/why only.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	QRS lines 2–14; the next comment is at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: butchers_broom_2026-0825-0620_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-0837.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or redundant quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Butcher’s Broom for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 matches ER frontmatter canonical_topic with & encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/17/2026”, the correct rendering of 2026-0817.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 495–499: mechanism, the effect that is actually delivered, the effect that is not, tolerability, and the product-attribution caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“tighten vein walls … less leaky” ← ER 495; “heaviness, aching, tiredness, tingling and evening swelling” ← ER 495; “underlying disease does not change” ← ER 495; “Well tolerated” ← ER 497/499; “three-ingredient product” ← ER 499.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“small blood vessels less leaky” and “three-ingredient product” replace capillary permeability and the branded combination; no acronym appears.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	“falls modestly” carries no numeric effect estimate.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the “Populations who should avoid Butcher’s broom” list at ER lines 332–339.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	QRS lines 571–578, eight <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s em-dash clauses (“— no human safety data at any dose”, “— these require anticoagulation, not a venotonic”, “— no paediatric dosing or safety data”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	”(≥160/100 mmHg untreated or unresponsive)”, “in the past 12 months”, “>3× upper limit of normal” and “(lymphocytic or collagenous)” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies eight such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map to the interaction bullets at ER lines 308–326.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten of the ER’s eleven bullets are carried; the omitted one (ER line 328) is the ER’s own explicit non-interaction, “complementary, not interacting”.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	QRS lines 586–601, ten <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “caution/monitor” verdict sentence and mitigation sentence is stripped; only the drug-class name and its example list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example lists retained for all eight bullets that carry them; trimming (silodosin, tranylcypromine, pseudoephedrine from the agonist list) shortens but never empties a parenthetical.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten such exposures and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at lines 365, 367 and 375.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The standardised single-agent dose, the combination regimen behind almost all the pooled evidence, and dose timing are the three execution decisions; the remaining ER bullets are comparative positioning or “no data” statements.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER contains twelve protocol bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; none is blank or placeholder.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Symptomatic onset (2–4 weeks) and objective onset (8–12 weeks) from ER line 422, plus the 12-week window within which the ER states the benefit-showing trials showed benefit (ER line 400).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Leg-symptom relief precedes swelling reduction, matching the ER’s own ordering of the two High-tier benefits (ER lines 160 and 166), with the outer 12-week decision point last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content; none is blank or placeholder.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at lines 400 and 422.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight items are the ER benefit headings at lines 160–208.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at QRS lines 541, 547, 550, 556 with correct tier assignment (2 / 1 / 3 / 2 items, matching the ER).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER heading text is carried; the ER’s Magnitude lines (risk ratios, numbers needed to treat, standardised mean differences) are all excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items are the ER risk headings at lines 238–286.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at QRS lines 613, 616, 619, 625 with correct tier assignment (1 / 1 / 4 / 2 items, matching the ER).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER heading text is carried; the ER’s risk-ratio and confidence-interval magnitudes are excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s inline glosses are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence trace to the ER Monitoring Protocol & Defining Success section, lines 454–464.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER table rows present: alanine aminotransferase, aspartate aminotransferase, fasting glucose, glycated haemoglobin, potassium, high-sensitivity C-reactive protein, ankle circumference — with the ER’s optimal ranges unchanged.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 744–748 condense ER line 454: baseline/4/12-week measures, 8-week liver enzymes, daily glucose for the first fortnight in diabetes, then annual and 6-monthly follow-up.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	The six items are the ER’s qualitative-marker bullets at lines 468–473.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER bullets present and none added, carried essentially verbatim.

Issues 17/08/2026 09:12

Pass rate 100.00%. No issues found.

Issues 17/08/2026 09:03

1. 4.5 — Sheet exceeds one A4 page: Uncondensed fields push the sheet past the single-page budget — time_2_sub (line 516) and marker_7_target (line 737) each run ~115+ characters inside narrow cells, and five Monitoring why cells plus monitoring_cadence (line 752) wrap to multiple lines; the Protocol panel, Key Interactions gate and Monitoring table alone already exceed the printable height.

Fixes 17/08/2026 09:03

1. 4.5 — Monitoring “Why” cells condensed: Shortened marker_1_why (“Detects the rare liver injury reported with Ruscus products” → “Detects the rare reported liver injury”), marker_2_why, marker_3_why, marker_5_why and marker_6_why so each fits a single line in the Why column.
2. 4.5 — Ankle circumference target shortened: marker_7_target reduced from “…from the individual’s own evening baseline counts as response” to “…≥0.5 cm reduction at 12 weeks vs own evening baseline”, cutting the tallest table row from four lines to two.
3. 4.5 — Monitoring cadence tightened: monitoring_cadence condensed to “…at baseline, 4 and 12 weeks; … daily glucose for the first fortnight in diabetes; then annual liver enzymes and 6-monthly limb reassessment.”
4. 4.5 — Time-to-effect subtexts condensed: Trimmed time_1_sub, time_2_sub (dropped the trailing “earlier measurement understates the effect” clause) and time_3_sub, plus action_3_sub, to cut the Protocol panel height.
5. 4.5 — Key Interactions example lists trimmed: Shortened the drug lists for alpha-adrenergic agonists, alpha-1 blockers and monoamine oxidase inhibitors, and dropped “with additive effects” from the venotonic-supplements item, keeping every interaction present per 9.5.
6. 4.5 — Contraindication wording compressed: Reworded the diabetes, liver-disease and hypersensitivity items (“above three times the upper limit of normal” → “>3× upper limit of normal”) while preserving all thresholds and time windows.

Issues 17/08/2026 08:55

1. 1.2 / 1.3 — Hedge dropped in At-A-Glance: [at_a_glance] (QRS line 434) renders the ER’s hedged mechanism claim as a definite one — ER line 495 reads “tighten vein walls and appear to make small blood vessels less leaky”, while the QRS states “tighten vein walls and make small blood vessels less leaky”, removing a qualifier the ER carries because the capillary-sealing evidence is animal-model only (ER line 136) and the driving mechanism is described as contested (ER line 138).

Fixes 17/08/2026 08:55

1. 1.2 / 1.3 — Hedge restored in At-A-Glance: Reinstated the ER’s qualifier in [at_a_glance], changing “tighten vein walls and make small blood vessels less leaky” to “tighten vein walls and appear to make small blood vessels less leaky”, matching ER line 495. The section remains within the 60-word limit at 59 words.

Issues 17/08/2026 08:46

1. 9.2 / 9.4 — Non-interaction listed as interaction: The final [caution_items] entry at line 609, “Compression therapy and endovenous ablation: complementary, not interacting”, both carries a trailing explanatory clause and states a non-interaction that the ER (line 328) explicitly excludes from the interaction set.
2. 12.3 — Qualifier retained on benefit: Line 549 renders the medium benefit as “Improved vein-specific quality of life (conflicted)”; the parenthetical qualifier is redundant detail the tier already encodes.

Fixes 17/08/2026 08:46

1. 9.2 / 9.4 — Non-interaction removed from gate: Deleted the [caution_items] entry “Compression therapy and endovenous ablation: complementary, not interacting”, which the ER explicitly identifies as not an interaction and which carried a trailing explanatory clause.
2. 12.3 — Qualifier stripped from benefit: Changed the medium benefit from “Improved vein-specific quality of life (conflicted)” to “Improved vein-specific quality of life”.

Issues 17/08/2026 08:41

1. 4.2 / 4.3 — Combination protocol label abbreviated: [action_2_label] at QRS line 463 reads “Combination protocol”, but the ER’s bold label at line 367 is “Combination protocol popularised by Pierre Fabre:”; the label is abbreviated rather than carried over verbatim.

Fixes 17/08/2026 08:41

1. 4.2 / 4.3 — Combination protocol label restored: [action_2_label] changed from “Combination protocol” to the ER’s verbatim bold label “Combination protocol popularised by Pierre Fabre”.